Andarine

Drug Profile

Andarine

Latest Information Update: 24 Aug 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GTx
  • Class
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cachexia

Most Recent Events

  • 24 Aug 2009 Discontinued - Phase-I for Cachexia in USA (PO)
  • 19 Mar 2004 GTx and Ortho Biotech have entered into a joint collaboration, license and Co-promotional agreement for andarine worldwide for Mens Health
  • 04 Mar 2004 Three phase I clinical studies have been completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top